Aurisco Pharmaceutical Co.,Ltd. (SHSE:605116) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Aurisco Pharmaceutical Co.,Ltd. (SHSE:605116) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
It is hard to get excited after looking at Aurisco PharmaceuticalLtd's (SHSE:605116) recent performance, when its stock has declined 14% over the past three months. However, a closer look at its sound financials might cause you to think again. Given that fundamentals usually drive long-term market outcomes, the company is worth looking at. In this article, we decided to focus on Aurisco PharmaceuticalLtd's ROE.
看了奥里斯科制药有限公司(SHSE: 605116)最近的表现,很难感到兴奋,当时其股票在过去三个月中下跌了14%。但是,仔细观察其稳健的财务状况可能会让你重新考虑。鉴于基本面通常会推动长期市场业绩,因此该公司值得关注。在本文中,我们决定重点介绍奥里斯科制药有限公司的投资回报率。
ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.
投资回报率或股本回报率是评估公司如何有效地从股东那里获得投资回报的有用工具。简而言之,投资回报率显示了每美元从其股东投资中产生的利润。
How To Calculate Return On Equity?
如何计算股本回报率?
The formula for return on equity is:
股本回报率的公式是:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
股本回报率 = 净利润(来自持续经营业务)÷ 股东权益
So, based on the above formula, the ROE for Aurisco PharmaceuticalLtd is:
因此,根据上述公式,奥里斯科制药有限公司的投资回报率为:
14% = CN¥255m ÷ CN¥1.9b (Based on the trailing twelve months to September 2023).
14% = 2.55亿元人民币 ÷ 19亿元人民币(基于截至2023年9月的过去十二个月)。
The 'return' refers to a company's earnings over the last year. That means that for every CN¥1 worth of shareholders' equity, the company generated CN¥0.14 in profit.
“回报” 是指公司去年的收益。这意味着,每获得价值1元人民币的股东权益,该公司就会产生0.14元人民币的利润。
What Is The Relationship Between ROE And Earnings Growth?
投资回报率与收益增长之间有什么关系?
Thus far, we have learned that ROE measures how efficiently a company is generating its profits. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.
到目前为止,我们已经了解到,投资回报率衡量的是公司创造利润的效率。根据公司选择将多少利润进行再投资或 “保留”,我们便能够评估公司未来创造利润的能力。假设其他一切保持不变,那么与不一定具有这些特征的公司相比,投资回报率和利润保留率越高,公司的增长率就越高。
Aurisco PharmaceuticalLtd's Earnings Growth And 14% ROE
Aurisco PharmaceuticalLTD的收益增长和14%的投资回报率
To start with, Aurisco PharmaceuticalLtd's ROE looks acceptable. Especially when compared to the industry average of 8.3% the company's ROE looks pretty impressive. This certainly adds some context to Aurisco PharmaceuticalLtd's decent 9.6% net income growth seen over the past five years.
首先,奥里斯科制药有限公司的投资回报率似乎可以接受。特别是与行业平均水平的8.3%相比,该公司的投资回报率看起来相当可观。这无疑为Aurisco PharmaceuticalLTD在过去五年中实现的9.6%的净收入增长增添了一些背景信息。
We then performed a comparison between Aurisco PharmaceuticalLtd's net income growth with the industry, which revealed that the company's growth is similar to the average industry growth of 11% in the same 5-year period.
然后,我们将Aurisco PharmaceuticalLTD的净收入增长与该行业进行了比较,结果显示该公司的增长与同期行业11%的平均增长率相似。
![past-earnings-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240312/0-d086ec3e12216d2279fffe7f96970b8f-0-469fa3e4698fc617ddee7fb2082ede2a.png/big)
Earnings growth is a huge factor in stock valuation. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. This then helps them determine if the stock is placed for a bright or bleak future. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if Aurisco PharmaceuticalLtd is trading on a high P/E or a low P/E, relative to its industry.
收益增长是股票估值的重要因素。无论如何,投资者应设法确定预期的收益增长或下降是否已计入其中。然后,这可以帮助他们确定股票是为光明还是暗淡的未来而布局。衡量预期收益增长的一个很好的指标是市盈率,它根据收益前景决定了市场愿意为股票支付的价格。因此,您可能需要检查Aurisco PharmaceuticalLTD相对于其行业是高市盈率还是低市盈率。
Is Aurisco PharmaceuticalLtd Efficiently Re-investing Its Profits?
Aurisco PharmaceuticalLTD 是否有效地将其利润再投资?
Aurisco PharmaceuticalLtd has a three-year median payout ratio of 30%, which implies that it retains the remaining 70% of its profits. This suggests that its dividend is well covered, and given the decent growth seen by the company, it looks like management is reinvesting its earnings efficiently.
Aurisco PharmaceuticalLTD的三年派息率中位数为30%,这意味着它保留了剩余的70%的利润。这表明其股息覆盖范围良好,鉴于该公司的可观增长,管理层似乎正在有效地对其收益进行再投资。
Besides, Aurisco PharmaceuticalLtd has been paying dividends over a period of three years. This shows that the company is committed to sharing profits with its shareholders.
此外,Aurisco PharmaceuticalLTD已在三年内派发了股息。这表明该公司致力于与股东分享利润。
Conclusion
结论
In total, we are pretty happy with Aurisco PharmaceuticalLtd's performance. Particularly, we like that the company is reinvesting heavily into its business, and at a high rate of return. Unsurprisingly, this has led to an impressive earnings growth. Having said that, looking at the current analyst estimates, we found that the company's earnings are expected to gain momentum. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.
总的来说,我们对奥里斯科制药有限公司的表现非常满意。特别是,我们喜欢该公司对其业务进行大量再投资,而且回报率很高。毫不奇怪,这带来了令人印象深刻的收益增长。话虽如此,从分析师目前的估计来看,我们发现该公司的收益有望增强。要详细了解分析师对公司的最新预测,请查看该公司的分析师预测的可视化。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。